Loading…
← CockpitCompetitor Analysis › 600855.SS Beijing Aerospace Changfeng Co., Ltd. Class AOpen in the cockpit ↗

Beijing Aerospace Changfeng Co., Ltd. Class A600855.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum weak 30
Mkt cap
$738M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$13.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-17.5 pp
WACC 9.4%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥10.96
1D-1.6%
1W-11.0%
1M-12.2%
3M-14.0%
6M-44.4%
YTD-47.9%
1Y-29.3%
ATR %4.5%
52w lowhigh63.5% off high

What Beijing Aerospace Changfeng does

Employees: 1,298

Beijing Aerospace Changfeng at a glance

Size Beijing Aerospace Changfeng (600855.SS) is a China Health Care company (Medical Specialties) with a market value of $738M, the 2770th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.96 on 18 Nov 2026.

Performance Over six months the shares fell 44.4%, against -13.5% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 10.2% over the last twelve months (peer median +9.1%); the operating margin is -18.9% (peer median 13.3%).

Valuation It trades at 4.5× enterprise value to sales against a peer median of 3.1× (5th most expensive of 21).

Capital Return on invested capital runs 17.5 points below its cost of capital (9.4% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 88600855.SS 55
Six months, rebased to 100: Beijing Aerospace Changfeng against the median of its 20 peers (local-currency closes).

Beijing Aerospace Changfeng financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.03BCN¥1.25BCN¥1.15BCN¥1.37BCN¥1.80B
Revenue growth—+8%-16%-24%—
Gross profitCN¥251MCN¥201MCN¥190MCN¥211MCN¥435M
EBITDAn/a-CN¥103M-CN¥206M-CN¥181MCN¥55.8M
Net income-CN¥164M-CN¥172M-CN¥246M-CN¥235MCN¥5.48M
Free cash flow-CN¥45.9M-CN¥41.8M-CN¥80.0M-CN¥93.2M-CN¥157M
Capital expenditureCN¥24.7MCN¥27.2MCN¥67.8MCN¥89.7MCN¥80.6M
Total debtCN¥177MCN¥239MCN¥343MCN¥375MCN¥387M

Quarterly statements and history in the cockpit →

Beijing Aerospace Changfeng competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%301367688179INMD6031083004530029506881083011223004632190300622VREX1302688410CTKBMLAB7575BBNX301234600855.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Aerospace Changfeng is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%2×4×6×8×301367688179INMD6031083004530029506881083011223004632190300622VREX1302688410CTKBMLAB75751501BBNX301234600855.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Aerospace Changfeng is the large dot.

Beijing Aerospace Changfeng competitors and peer comparison

How Beijing Aerospace Changfeng compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Aerospace Changfeng against its 20 peers (data as of 18 Nov 2026)
Measure600855.SSPeer medianRank in peer set
1-month return-12.2%-8.5%8th lowest of 21
6-month return-44.4%-13.5%lowest of 21
Distance from 52-week high-63.5%-37.6%lowest of 21
Revenue growth (TTM)-10.2%+9.1%3rd lowest of 21
Operating margin-18.9%13.3%3rd lowest of 21
EV / Sales4.5×3.1×5th most expensive of 21
ROIC minus cost of capital-17.5 pp+1.4 pp3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%4.5×n/an/a
BMC Medical 301367.SZChina$737M-17%+37%17%1.8×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%5.8×17.1%+24.2%
InMode INMDUnited States$741M-8%+2%18%0.6×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%1.7×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%2.8×-1.9%+11.8%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%1.5×n/an/a
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%7.8×27.9%+9.9%
Caina Technology 301122.SZChina$721M+36%+61%0%7.7×n/an/a
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%2.3×7.9%-10.2%
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%3.6×3.8%+105.8%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%3.1×-3.4%+15.7%
Varex Imaging VREXUnited States$771M+79%+5%8%1.2×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%3.2×9.6%+15.5%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%3.6×16.2%+25.9%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%2.6×n/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%3.6×21.3%+13.2%
Japan Lifeline 7575.TJapan$703M+34%+6%19%1.7×-9.5%+2.9%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%3.6×-3.3%+23.5%
Beta Bionics BBNXUnited States$779M+42%+44%-73%4.3×n/an/a
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%10.3×31.8%-0.6%

Questions

Which companies are Beijing Aerospace Changfeng's closest peers?
The cockpit's peer set: BMC Medical (301367.SZ), Shanghai Aladdin Biochemical Technology (688179.SS), InMode (INMD), Shanghai Runda Medical Technology (603108.SS), Jiang Xi Sanxin Medtec (300453.SZ), Allmed Medical Products (002950.SZ), Sino Medical Sciences Technology (688108.SS), Caina Technology (301122.SZ).
Is Beijing Aerospace Changfeng expensive compared with its peers?
On ev / sales it trades at 4.5× against a peer median of 3.1×, 5th most expensive of 21 in its peer set.
How has Beijing Aerospace Changfeng stock performed?
Over six months to 18 Nov 2026 the shares returned -44.4% against -13.5% for the median peer; over one year -29.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.